Nicholas Tubach
Chief Executive Officer
Nicholas Tubach is the cofounder of four early-stage biotechnology
companies: Propion Inc., Propion Therapeutics, Repoxegen Therapeutics,
and Synap Biotech, for which he has recruited a number of experienced
cofounders.
Dr. Jan Scicinski
Head of Medicinal Chemistry
Dr Jan Scicinski is an experienced drug discovery and development
scientist, executive, and problem solver with a successful track
record in new pharmaceutical product discovery and development.
He has more than 30 years experience in the pharmaceutical and biotech
industries, in both start-up and large corporate environments (GSK,
Nuada, ALZA, EpicentRx), providing leadership for programs in drug
discovery from hit identification to lead selection and for
development projects including CMC, IND-enabling activities, clinical
trial operations and regulatory filings and communication.
Dr. Scicinski is a Fellow of the Royal Society of Chemistry with
Chartered Chemist Status and holds a PhD from Cambridge University and
BSc hons from Imperial College, London. He has co-authored over 170
peer-reviewed publications, patents, abstracts and book chapters.
Dr. Daniel Winer
Head of Translational Research
Dr. Winer is a key opinion leader in immunology, cell biology, and
metabolic disease research. He is currently an Associate Professor at
The Buck Institute for Research on Aging and an Assistant Professor at
the University of Toronto.
Dr. Winer is the recipient of several awards including the Hubert
Wolfe Award in Endocrine Pathology, the Benjamin Castleman Award for
human pathology research (sponsored by the United States and Canadian
Academy of Pathology and the Massachusetts General Hospital), the
Amgen early investigator award (Endocrine Society), and the Canada
Research Chair in Immunometabolism.
Marco Quarta
Strategic Advisor
Dr. Marco Quarta earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology at Stanford University School of Medicine. He then directed at Stanford School of Medicine/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine.
He is now founder and CEO of Rubedo Life Sciences, driving its mission to develop treatments for chronic age-related diseases and extend healthspan, and co-founder of the rejuvenation company, Turn Biotechnologies, based on his work conducted at Stanford University on transient epigenetic reprogramming. He additionally sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) and research board at the Center for Healthcare Innovation (CHI).
